首页> 外文期刊>Hepatitis Monthly >Diagnostic Value of Serum Adenosine Deaminase and Its Isoenzymes for Autoimmune Liver Disease
【24h】

Diagnostic Value of Serum Adenosine Deaminase and Its Isoenzymes for Autoimmune Liver Disease

机译:血清腺苷脱氨基酶及其同工酶对自身免疫性肝病的诊断价值

获取原文
       

摘要

Background: Adenosine Deaminase (ADA) has been found to be involved in autoimmune disease progression.Objectives: We aimed to evaluate the diagnostic value of serum ADA activity in Autoimmune Liver Disease (AILD).Methods: The study included 50 AILD patients, 33 viral hepatitis patients, and 60 healthy subjects. The serum levels of total AdenosineDeaminase (tADA) and its isoenzymes (ADA1 and ADA2) were determined. The Receiver Operating Characteristic (ROC) curveanalysis was used to evaluate the diagnostic performance of serum ADA activity.Results: Our results showed that the serum tADA and ADA2 levels were significantly higher in AILD patients (tADA: 19 (IQR 14 - 24)U/L; ADA2: 16 (IQR 10 - 19) U/L) than in healthy controls (tADA: 9 (IQR 7 - 11) U/L; ADA2: 7 (IQR 6 - 9) U/L), while there was no significantdifference in serum ADA1 activity between AILD and healthy subjects. Based on the ROC curves analysis, the optimal cutoff values ofserum tADA and ADA2 activity were 11.5 and 9.5 U/L, respectively. At this level, the highest diagnostic values of tADA (specificity: 83.3%;sensitivity: 88%) and ADA2 (specificity: 85.0%; sensitivity: 82%) were obtained. Moreover, our results showed no significant differencein serum tADA, ADA1, and ADA2 levels between AILD and viral hepatitis patients (P = 0.049; P = 0.29; P = 0.054).Conclusions: Serum ADA activity can be used to distinguish AILD patients from healthy subjects, but it cannot be used in the differentialdiagnosis of AILD and viral patients.
机译:背景:已发现腺苷脱氨素酶(ADA)参与自身免疫性疾病进展。目的:我们旨在评估自身免疫性肝病中血清ADA活性的诊断价值(AILD)。方法:该研究包括50例患者,33名病毒肝炎患者和60名健康受试者。确定了总腺苷酰胺酶(TADA)及其同工酶(ADA1和ADA2)的血清水平。使用接收器操作特征(ROC)Curveansis分析来评估血清ADA活性的诊断性能。结果:我们的结果表明,血清TADA和ADA2水平在AILD患者中显着高(TADA:19(IQR 14-24)U / l; ADA2:16(IQR 10-19)U / L)比健康对照(TADA:9(IQR 7 - 11)U / L; ADA2:7(IQR 6 - 9)U / L),同时存在血清ADA1之间没有显着的血清和健康受试者之间的活动。基于ROC曲线分析,Serum TADA和ADA2活性的最佳截止值分别为11.5和9.5 U / L.在这个水平,坦达的最高诊断价值(特异性:83.3%;敏感性:88%)和ADA2(特异性:85.0%;敏感度:82%)。此外,我们的结果表明,血清TADA,ADA1和ADA2患者之间没有显着差异(P = 0.049; P = 0.29; P = 0.054)。结论:血清ADA活性可用于区分AILD患者的健康患者受试者,但它不能用于血液和病毒患者的差异诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号